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Background: A non-invasive method to predict the malignancy of surgery-candidate solitary pulmonary 
nodules (SPN) is urgently needed. 
Methods: Super-depth next generation sequencing (NGS) of 35 paired tissues and plasma DNA was 
performed as an attempt to develop an early diagnosis approach. 
Results: Only ~6% of malignant nodule patients had driver mutations in the circulating tumour DNA 
(ctDNA) with >10,000-fold sequencing depth, and the concordance of mutation between tDNA and ctDNA 
was 3.9%. The first innovative whole mutation scored model in this study predicted 33.3% of malignant 
SPN with 100% specificity. 
Conclusions: These results showed that lung cancer gene-targeted deep capture sequencing is not 
efficient enough to achieve ideal sensitivity by simply increasing the sequencing depth of ctDNA from 
early candidates. The sequencing could not be evaluated hotspot mutations in the early tumour stage. 
Nevertheless, a larger cohort is required to optimize this model, and more techniques may be incorporated 
to benefit the SPN high-risk population. 
Keywords: Solid pulmonary nodule; early diagnosis; circulating tumour DNA (ctDNA); lung cancer; tumor 
mutational burden (TMB)
Submitted Mar 15, 2018. Accepted for publication Mar 26, 2018.
doi: 10.21037/jtd.2018.04.09
View this article at: http://dx.doi.org/10.21037/jtd.2018.04.09
S821Journal of Thoracic Disease, Vol 10, Suppl 7 April 2018
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2018;10(Suppl 7):S820-S829jtd.amegroups.com
Introduction
Lung cancer continues to be the leading cause of cancer 
mortality in both men and women worldwide (1). Early 
diagnosis is crucial for improving lung cancer survival, given 
that the prognosis of stage I lung cancer is considerably 
favourable with a 5-year survival rate of more than 70% 
compared with metastatic late-stage disease (<5% survival) (2). 
Currently, the most successful method for early detection is 
low-dose computed tomography (LDCT) scan screening, 
which was demonstrated by the National Lung Cancer 
Screening Trial (NLST) study to reduce mortality by 20% 
compared with chest radiograph screening of lung cancer (3). 
The widespread application of LDCT has led to a 
significant increase in the detection of lung nodules (4,5). 
The prevalence of solitary pulmonary nodules (SPN) 
(<3 cm in diameter) is 10–20% in the United States (6) and 
is higher in people with Asian ancestry probably due to 
genetic and environmental factors. Most SPN found in CT 
scans are benign, even among high-risk populations such 
as smokers. A few algorithms or prediction models based 
on nodule features in the CT scan have been developed; 
however, their accuracy remains unsatisfactory (7). On one 
hand, timely identification of malignant nodules is crucial 
because they represent a localized disease and are potentially 
curable. On the other hand, it is costly and possibly harmful 
to manage an SPN with radiation exposure from repeated 
CT scans or invasive procedures such as biopsy or surgical 
resection that are associated with potential morbidity and 
induce unnecessary anxiety. Therefore, there is a critical 
need for additional tests that can further stratify the SPN 
found by LDCT as malignant and non-malignant. 
Non-invasive tests are preferable. 18F-FDG-PET/CT 
only slightly adds to diagnostic value, and its use is limited 
by its low cost-effectiveness (8). A few plasma biomarkers, 
such as CEA and CA-125, have been used to screen and 
diagnose lung cancers (9-11). However, the sensitivity 
of serum biomarkers is relatively low because they are 
proteins and thereby will be elevated only when the tumour 
burden is high. Therefore, there is no sufficiently reliable 
biomarker that exhibits both high sensitivity and specificity 
for the diagnosis of malignant SPN. ctDNA represents a 
promising option: it is released or excreted by tumour cells, 
circulates in the blood of a patient with cancer, and can 
serve as direct evidence of malignancy (12).
Because of the diverse mutation pattern of lung 
cancer, it cannot be evaluated using conservative single-
gene mutations or hotspot mutations. Unlike PCR-based 
techniques, NGS simultaneously allows the detection of 
a wide spectrum of loci. Comprehensive analyses could 
theoretically increase sensitivity. In addition, genetic 
mutations should be more reliable than other qualitative 
markers (e.g., antibody or micro-RNA level), which require 
tricky cut-offs.
Previously, a report described using the total plasma 
cell-free DNA (cfDNA) level to discriminate non-small 
cell lung cancer (NSCLC) from benign lung pathologies 
and healthy controls with 86.4% sensitivity and 61.4% 
specificity (13). However, debates remain regarding the 
lower limit of detection of ctDNA NGS. We hypothesized 
that the analysis of the lung cancer-related somatic 
mutations from ctDNA could provide better opportunities 
for minimally invasive SPN diagnosis. We hereby aimed 
to develop a practical tool based on ctDNA profiling and 
super-deep sequencing methods and test its ability to 
distinguish between malignant and non-malignant SPN 
in this pilot study. However, debates remain regarding the 
lower limit of detection of ctDNA NGS.
Results
Lung peripheral nodule clinical features and tumour 
serum protein marker classification 
A total of 1,254 consecutive candidate patients were reviewed 
for resection of lung peripheral nodules in the First Affiliated 
Hospital of Guangzhou Medical University. In postoperative 
pathological examination, 69% of lung peripheral nodules 
were diagnosed as malignant, and the distribution of 
malignant SPN subtypes is shown in Figure S1. Almost 80% 
of SPNs were adenocarcinoma, which included 13% AAH 
(atypical adenomatous hyperplasia)/AIS (adenocarcinoma in 
situ)/MIA (minimally invasive adenocarcinoma) malignancy 
patients. Surgery and biopsy were risky for the patients 
and could cause complications. A non-invasive method was 
required to identify the malignancy of surgery-candidate 
lung peripheral nodules. Tumour serum protein markers 
(CEA, NSE, CA125, CA153, and CYFRA21-1) are 
conventionally used to determine the malignancy of SPN. 
However, only CEA and CYFRA21-1 in malignant SPN 
were significantly higher than in non-malignant SPN. The 
expression of NSE and CA153 in this statistical cohort was 
not different between malignant and benign cases based 
on the p-value calculated by the unpaired t-test (Figure 1). 
The expression of CA125 in benign SPN was significantly 
higher than in malignant SPN. The mean expression of 
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serum protein markers was similar. Therefore, this signature 
limits serological indicators as an accurate diagnosis 
of early lung cancer. Neither CEA (cut-off 5 ng/mL, 
specificity 90.1%, sensitivity 23.8%) or CYFRA21-1 (cut-
off 3.3 ng/mL, specificity 80.6%, sensitivity 28.5%) nor 
their combination (specificity 77.6%, sensitivity 42.1%) 
could precisely predict malignancy. When using 10 ng/mL 
as the cut-off, CEA achieved a specificity of 97.1%, but the 
sensitivity was only 9.7%.
ctDNA seemed to be a good option as it has been largely 
reported and named as a non-invasive method for patients’ 
targeted genes tests and recurrent monitoring (14,15). In 
this study, both surgically resected lung peripheral nodules 
and plasma DNA were investigated by extra-deep high 
throughput sequencing of at least 10,000-fold depth to 
classify malignancies or non-malignancies in the early stage of 
lung cancer. The pipeline of this research is shown Figure S2. 
Thirty-five prospective samples were consecutively 
collected to perform the next generation sequencing (NGS) 
to develop a non-invasive malignant peripheral nodule 
prediction method. All the lung surgery candidate nodules, 
formalin-fixed, paraffin embedded (FFPE) tissues, and 
corresponding blood samples were collected as controls. 
Clinical summary information of the selected patients with 
lung pulmonary nodules is shown in Table 1; 62.9% of the 
patients were males, and 37.1% were females. Clinical 
histological results identified malignant peripheral nodules 
in 31 out of 35 patients and benign peripheral nodules in 
the remaining 4 patients. Out of 31 malignant SPNs, 81% 
of patients were diagnosed with lung adenocarcinoma, 
which had a much higher distribution than our statistical 
cohort, likely because of the relatively small sample size. 
All included cases were in clinical stage I. In postoperative 
pathological evaluation, 83.9% of the patients remained 
in stage I, while 29% of patients had advanced to stage II 
and III which were diagnosed postoperatively by incidental 
finding of positive lymph nodes. Therefore, all cases are 
necessary to be screened by NGS to explore the genomic 
profile. Each sample’s detailed clinical information is 
recorded in Supplementary Table S1. 
Landscape of somatic mutations and driver genes
DNA from white blood cells was used as a corresponding 
normal control to detect somatic mutations from FFPE and 
ctDNA samples. All of the samples were analysed by lung 
cancer target capture and sequenced by the Illumina HiSeq 
2000 instrument. The lung cancer panel included the exon 
region of lung cancer driver genes and top mutational lung 
adenocarcinoma-related genes, based on the COSMIC 
Figure 1 Clinical distribution of all SPNs. The pie chart (A) shows the distribution of SPN histological types. The expression comparison of 
tumour serum protein markers is shown in (B). P values were calculated by an unpaired t-test. Different colour indicates different markers; 
dot indicates benign SPN; little triangle indicates malignant SPN. Other cancer, malignant SPNs that cannot be categorized by the listed 
cancer types. SCLC, small cell lung cancer; SPN, solitary pulmonary nodule. 
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database (Table S2). Followed by deep sequencing, at least 
99.9% of the target genomic regions of each case were 
covered (Table S3). The median depths were 600× (from 
171 to 1,941) for the 38 FFPE samples, 823× (from 524× to 
2,543×) for the 38 normal control samples, and 1,896× (from 
610 to 7,653) for the 35 ctDNA samples. 
In total, 89 non-silent SNV/InDels/SV (range from 
0 to 11) were discovered in the 31 tumour tissue samples. 
No mutations were detected from the 4 benign pulmonary 
nodules (Figure 2). Twenty-nine of the 31 cancer samples 
contained at least one non-silent mutation, and non-silent 
mutations were detected in all of the lung adenocarcinomas. 
The two samples in which mutations were not detected 
were lung carcinoid tumours. This might be because of the 
limitation of the panel’s gene list, which was based on lung 
adenocarcinoma and was not available for lung carcinoid 
tumours and squamous carcinoma. Each sample’s detailed 
mutational information, excluding that of SV, is shown in 
Table S4. Four fusions were detected in 3 samples, and 2 of 
them (ALK, ROS1) were found in sample S23_A. ALK was 
found in sample S5_A, and RET was found in sample S27_
A. However, only 3 out of 4 were successfully validated by 
immunohistochemistry, except ROS1 fusion in sample S23 
(Table S5). Twenty-eight non-silent mutations (SNV/InDel) 
were detected in the corresponding plasma samples. Only 
1 non-silent mutation was detected in the plasma of benign 
sample S32_N (Figure 2, Table S6). Clinical information of 
each patient is shown in Figure 2, with the distribution of 
stage, subtypes, sample types, and gender. The malignant 
SPN were divided into two groups according to the 
tumour stage in Figure 2 (stage I vs. stage II-III). For the 
patients with SPN, each patient’s mutational number had 
no difference in the tissue or plasma samples (Figures 2,S3). 
Compared with the mutations in the tissue of benign cases, 
mutations detected in the tumour tissue had a significantly 
higher mutational ratio. The mutational number from 
ctDNA was also assessed with respect to the size of 
SPN or the mutations in tissue, but no correlation was 
found (Figures 2,S4). After comparison of the mutational 
consistencies between tissue and plasma (Figure S5), only 6 
out of 152 mutations detected in FFPE were found in the 
corresponding ctDNA samples; the concordance between 
ctDNA and FFPE samples was much lesser than that in a 
previously reported study (16). Even more, 5 out of the 6 
overlapping mutations came from one sample (S8_A), which 
shows a lack of efficacy in early stage ctDNA evaluation to 
some degree.
Well-known driver genes were detected in 22 out of 31 
(71%) malignant FFPE samples, and the frequency of each 
driver gene was as follows: EGFR: 46%, KRAS: 3%, ALK/
ROS1/RET fusion: 11%, BRAF: 3%. The frequency of each 
driver gene was different from that in our previous study 
(17,18), especially KRAS, which might be because of sample 
size limitation and the sequencing panel, which was designed 
only for lung adenocarcinoma. Except for sample S23_A 
with non-validation ROS1 fusion, all the other SPNs had a 
unique driver gene (Figure 3). Of the EGFR-positive SPN 
samples, 37.5% had compound EGFR mutations; 8 samples 
contained L858R mutations, and 7 samples had exon 19 
deletions (Table 2). Even 3 EGFR mutations were found in 
sample S22_A. Although all the EGFR compound mutations 
were rare, SNV/InDel and the co-EGFR mutational ratio 
were higher than in a recent Asian study (19), This previous 
study proved that patients with a single EGFR mutation had 
better survival rates than patients with compound EGFR 
Table 1 Clinical information of patients with lung pulmonary  
nodules sampled for ultra-deep sequencing
Clinical feature (35 total samples) Data
Age at surgery [median, range] 59 [27–81]
Gender
Male 22
Female 13
Cancer type
Benign 4
Cancer 31
AIS/MIA 2
Adenocarcinoma 25
Squamous carcinoma 1
Other cancer 3
Clinical tumour stage
I 35
Pathological tumour stage
I 21
II* 5
III# 4
NA 1
*, unexpected N1 lymph nodes incidentally found by pathological 
examination; #, unexpected N2 lymph nodes incidentally found 
by pathological examination. AIS, adenocarcinoma in situ; MIA, 
minimally invasive adenocarcinoma.
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mutations, and there were no differences in disease-free 
survival rates. All the EGFR co-mutation samples had similar 
allele frequencies of each EGFR mutation. Driver mutations 
were found in only two ctDNA samples, both of which 
were mutated in EGFR, but the EGFR driver mutation in 
sample S4 was different in the tumour tissue and plasma. An 
EGFR compound mutation (L858R + S768I) was detected 
both in sample S8_A tissue and plasma samples. Overall, the 
extremely low driver mutation concordance between the 
FFPE and corresponding ctDNA suggested that ctDNA 
content in SPN patients was also too low to be efficiently 
sequenced by the NGS method. ddPCR was performed as a 
sensitive tool for low-frequency mutation testing to validate 
known hotspot driver mutations detected in the FFPE and 
Figure 2 Somatic mutation landscape of FFPE and ctDNA samples. (A) The bars represent the non-silent mutational number of each 
sample. The samples are sorted by the tumour stage [benign, stage I (AIS/MIA, adenocarcinoma), and stage II–III] and number of non-silent 
mutations. Mutational type is distinguished by colour. ctDNA mutational landscape is shown in (B). The major clinical information (plasma, 
gender, tumour stage, cancer subtype) is shown in (C). ctDNA, circulating tumour DNA; AIS, adenocarcinoma in situ; MIA, minimally 
invasive adenocarcinoma; FFPE, formalin-fixed, paraffin embedded.
Figure 3 Driver gene mutations detected in paired samples. Distribution of driver gene mutational frequency is shown in (A), and each 
patient’s driver gene in FFPE and plasma samples is shown in (B). FFPE, formalin-fixed, paraffin embedded.
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ctDNA samples. 
Driver mutation validation by ddPCR
ddPCR is a well-known low-frequency mutation detection 
platform and serves as an efficient tool to test the reliability 
of sequencing data from NGS. As for the limitation of 
ctDNA quantity, only 6 samples with EGFR/KRAS hotspot 
driver mutations were validated to confirm the mutation 
accuracy and frequency detected by NGS (Table 3). 
Meanwhile, four corresponding FFPE samples were also 
randomly selected to be validated by ddPCR as a control. 
A similar mutant allele frequency of FFPE samples was 
observed with NGS and ddPCR. Results from ddPCR 
detection indicated that there was a good concordance 
between the NGS and ddPCR detection, providing 
favourable evidence that the sequencing data are reliable. 
The ddPCR results helped prove that the mutational 
concordance between ctDNA and FFPE of SPN was much 
lower than in a previous study (16).
Malignant lung peripheral nodule prediction
A new model used to predict the malignancy of lung 
peripheral nodules based on the 35 plasma samples was 
developed using two matrixes: (I) the score of mutation 
(MS) contributing to the lung adenocarcinoma genesis and 
development and (II) the tumour burden of cfDNA (TMB), 
which was used to evaluate the whole mutational frequency 
within the panel region. Cancer gene census from the 
COSMIC database was used to divide the mutational genes 
into three groups: (I) oncogene, (II) tumour suppressor 
gene, and (III) non-cancer-related gene. Well-known 
LUAD driver mutation was added as a fourth group (such 
as EGFR:L858R, KRAS:G12V, ROS1/RET/ALK fusion, and 
so on). The score of each mutation was assigned based on 
the formula below:   
3
2
1
0
2
2  
( )  =  
2  
2  
i i
 class1 : well - know LUAD driver mutation 
class2 : oncogenic mutation except class1
MS = sum S S
class3 : mutation in tumor suppressor gene
class4 : mutation except before class
i = mutation 







in one sample
Table 2 EGFR mutational landscape
EGFR mutational type N=16 %
L858R 5 31.2
Exon 19 deletion 4 25.0
Rare SNV 1 6.3
Co-mutation 6 37.5
L858R + R889G 1 6.3
L858R + S768I 1 6.3
L858R + V834L 1 6.3
Exon19del + L833V 1 6.3
Exon19del +A750Pro 1 6.3
Exon19del + N756H+ A755G 1 6.3
Table 3 Mutational frequency detected by NGS and ddPCR
Sample ID Gene Mutation Sample type NGS freq ddPCR freq
S8_A EGFR p.L858R ctDNA 0.0094 0.0049
S8_A EGFR p.L858R FFPE 54.70% 48.21%
S6_A EGFR p.L858R ctDNA Negative 1.7%
S6_A EGFR p.L858R FFPE 16.77% 16.86%
S9_A EGFR p.L858R ctDNA Negative Negative
S9_A EGFR p.L858R FFPE 24.08% 20.20%
S19_A EGFR p.L858R ctDNA Negative Negative
S24_A EGFR p.L858R ctDNA Negative Negative
S3_A KRAS p.G12C ctDNA Negative Negative
S3_A KRAS p.G12C FFPE 24.54% 22.35%
NGS, next generation sequencing; ctDNA, circulating tumour DNA; FFPE, formalin-fixed, paraffin embedded.
S826
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All the potential mutational reads in the panel except 
germline mutations, which were identified by the normal 
control, were used to calculate the value:
( )
( )
i
i
sum NTMD
sum D
i = all the mutant sites except germline mutations
=
Di represents the reads of genomic i-th site; Ni represents 
the summary reads of non-reference base at potential 
mutation i. 
Based on the method developed in our study, the MS 
and TMB values of each sample are shown in Figure 4. 
The green dot represents benign samples. Thus, all four 
benign samples were distributed in the region within 
TMB ≤0.2, MS ≤2. If TMB =0.3 or MS =4 was used as 
the cut-off value for malignant SPN prediction, 33.3% 
of malignant adenocarcinoma samples could be predicted 
accurately based on the ctDNA samples. In contrast, the 
sensitivity of CEA (cut-off 10 ng/mL with 97% specificity) 
was only ~10%, which was lower than the mutation model 
prediction.
Discussion
LDCT, as an imaging tool for early lung cancer screening, 
provided insufficient benefit to participants in this study. It 
is reported that 39.1% of all participants in the LDCT arm 
of the trial had at least one positive screen, and 96.4% of 
these initial positive screenings represented false positives 
for lung cancer (20). Overabundance of false positives 
could lead to higher screening costs and unnecessary 
invasive procedures on candidates who do not actually 
have lung cancer (21). According to our thousands of 
medical records, we found that nearly 30% of peripheral 
nodules in lung surgery candidates were non-malignant, 
and tumour serological markers do not reliably diagnose 
malignant nodules with high sensitivity. It seemed that 
protein biomarkers from serum played a less important 
role and produced false signals during the test. As for the 
non-malignant cases, some patients underwent operations 
because of false prediction, whereas most of the rest chose 
surgery out of fear of the possibility of malignancy. Thus, 
ctDNA is defined as a more reliable tool to deliver more 
specific information for both patients’ and physicians’ 
reference, also to further define the high-risk population, 
and to provide a more cost-effective method for diagnosis. 
ctDNA may provide an opportunity for accurate diagnosis 
with the advantages of non-invasiveness and no bias of 
heterogeneity. 
Peripheral nodule DNA from surgery candidates had 
no significant correlation with tumour size and stage, but 
mutational numbers were significantly different between 
the benign and malignant nodules. Driver mutations 
were detected in 71% of malignant nodules. As for DNA 
mutations from the SPN plasma, advanced tumorigenesis 
stages and SPN size had no significant influence on somatic 
Figure 4 Benign/malignant SPN distribution. TMS and TMB of SPN distribution, which was calculated by in-house software. Different 
colour indicates different type of SPN. Other cancer, malignant SPN except adenocarcinoma. TMB, tumour mutational burden; TMS, 
ctDNA mutational score; SPN, solitary pulmonary nodule.
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mutations. Moreover, the difference between benign 
nodules and malignant nodules was not significant. Only 
~3.9% of DNA mutations from lung nodules could also 
be detected in the respective ctDNA by the 10,000-fold 
sequencing. The concordance of hotspot driver mutations 
between the malignant nodule DNA and the corresponding 
ctDNA was only 5.8%, which was much lower than the 
85% concordance of cancer tissue DNA and ctDNA in 
the advanced tumour stage (22). Meanwhile, there was 
no significant difference in concordance between the 
stage I and those of stage II and III which were diagnosed 
postoperatively by incidental finding of positive lymph 
nodes. This might because the early ctDNA signal of 
peripheral nodules had not been released into the blood 
system, or the early DNA mutation frequency was too 
low to be detected with nowaday sequencing approaches. 
Thus, improving sensitivity of tumour detection should 
not be attempted through increasing depth or coverage of 
sequencing. Somatic mutations were significantly different 
between benign and malignant tissue DNA but not 
ctDNA, given that it could not be tested and evaluated with 
conservative single-gene mutations and hotspot mutations 
in the early tumour stage due to the possible mechanisms 
and pathways. Interestingly, somatic mutations were also 
found in benign nodules, and most of the ctDNA mutations 
were not detected in FFPE samples, which needed further 
large-scale validation study.
Mutation concordance (including driver mutation) also 
suggested that predicting malignant nodules through driver 
mutation detection based on ctDNA has limited application. 
This finding encouraged us to grade and score all of the 
specific mutations to set up a prediction model according to 
how strongly the mutations correlate with lung cancer. The 
model first integrated the whole mutational differences, 
which not only included ‘tumour mutational burden’ but 
also evaluated the influence of ‘potential mutation’. It 
overcame the limitation of ctDNA low-frequency mutation 
detection by NGS. According to this model, we could 
predict 33.3% of malignant patients (sensitivity) with 100% 
specificity. Therefore, circulating cfDNA from patients 
with early lung cancer could reasonably accelerate early 
diagnosis by ultra-deep sequencing of at least 10,000-folds 
depth (>1,000-fold unique reads depth) and whole tumour 
mutation evaluation. This model was the first non-invasive 
method to predict the malignancy based on ctDNA, which 
could benefit more than one-third of pulmonary nodule 
candidates. The potential clinical application of this tool, 
after extensive validation, is supplemental to LDCT, which 
yields a great number of false positive cases (7). The high 
specificity (100%) of the ctDNA genetic model can help 
us ‘rule in’ some cases (~30%) that are highly suspected to 
have malignant disease and should be subjected to surgery 
with great confidence. 
More work shall be done in further studies. Because of 
the relatively low concordance of tissue DNA and ctDNA 
mutations, it was obvious that lung cancer genes-targeted 
capture sequencing was not efficient enough to diagnose 
with ideal sensitivity by simply increasing sequencing 
depth or coverage of ctDNA from early candidates. To 
achieve clinical utility, we propose that sequencing panel 
contents could be expanded from lung adenocarcinoma to 
other subtypes to better depict the performance for whole 
lung nodule patients. This model also shall be optimized 
by following larger cohort WGS sequencing data and 
correlated clinical data so that more cancer related gene 
mutations can be established in this mutational model for 
more sensitive differentiation in future studies. Therefore, 
following the remarkable findings of the cfDNA study, 
ctDNA could still play an important role in diagnosing 
nodules identified by LDCT or biomarkers as benign 
or malignant (21). The field is still rushing towards the 
identification of screening- or diagnostic-specific markers 
for malignant circulating cfDNA. Other techniques 
with theoretically higher sensitivity, such as multiplex 
methylation or cancer-related antibodies detection, might 
be incorporated to establish a multidimensional, powerful 
tool for early diagnosis.
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Supplementary
Methods
Patient materials
A total of 1,254 consecutive candidate patients were 
reviewed following the IRB-approved protocols for 
resection of lung peripheral nodules in the First Affiliated 
Hospital of Guangzhou Medical University from January 
2015 to November 2016. The 35 plasma and formalin-fixed, 
paraffin embedded (FFPE) tissue samples were collected 
from patients with lung peripheral solitary nodules ≤3 cm 
in diameter of varying size and differentiation. Complete 
ground glass nodules (GGNs), which were thought to be 
highly correlated with either non-invasive malignancies or 
benign changes, were not included in this study. This study 
is approved by ethical review board of our institution (No. 
2015-25).
Blood cell/FFPE cell library preparation and NGS
The library was constructed by shearing peripheral blood 
cell DNA with an ultrasonoscope to generate fragments 
with a peak of 250 bps, followed by end repair, A-tailing, 
and ligation to the Illumina-indexed adapters according 
to the standard library construction protocol (23). Target 
enrichment was performed on the designed cancer-related 
gene capture probe (NimbleGen, Roche Sequencing, 
Pleasanton, CA, USA). Sequencing was performed with 
2×101 bp paired-end reads and an 8-bp index read on an 
Illumina Hiseq 2,500/4,000 platform (San Diego, CA, USA).
ctDNA library preparation and NGS
Blood samples were collected by different hospitals in 
China using Cell-Free DNA BCT® blood collection tubes 
(Streck, La Vista, NE, USA) and transported to a clinical 
diagnosis lab in Tianjin. The tubes were centrifuged at 
1,600 g/min for 10 min. Then, we transferred the plasma 
to 1.5-mL tubes and centrifuged at 18,000 g/min for 5 min 
to remove any remaining cells and cellular debris. Finally, 
we transferred the supernatant to a fresh tube and stored it 
at −80 ℃. The ctDNA from each 2-mL volume of plasma 
was extracted using the QIAamp Circulating Nucleic 
Acid Kit (QIAGEN, Hilden, Germany) according to the 
manufacturer’s instructions. We quantified the ctDNA 
isolated from plasma by the Qubit dsDNA HS Assay Kit 
(Invitrogen, Carlsbad, CA, USA). ctDNA purified from 
plasma was used in the subsequent NGS panel sequencing 
assays. The library for ctDNA was constructed with the 
KAPA LTP Library Preparation Kit for Illumina Platforms 
(Kapa Biosystems, Wilmington, MA, USA) following the 
manufacturer’s instructions without modification (24). 
Sequencing was performed with 2×101 bp paired-end reads 
and an 8-bp index read on an Illumina Hiseq 2,500/4,000 
platform.
SNV/InDel calling
Raw reads were first processed by removing adaptors and 
filtering low-quality reads using SOAPnuke (http://soap.
genomics.org.cn/) before aligning to the human reference 
GRCh37 using BWA aligner (v0.6.2-r126) (25) and 
removing PCR duplications by PICARD (v1.98). Then, 
local realignment and base quality score recalibration 
were performed using GATK (v2.3-9) (26). Subsequently, 
an in-house software was used to call candidate single 
nucleotide variants (SNV) using the Bayesian model, after 
which SNV with strand bias and read location bias were 
filtered using the Fisher’s exact test and Kolmogorov-
Smirnov test separately (27). Then, SNVs in the local 
control set were filtered. SNVs were scored according to 
GC content, adjacent SNV and InDels, multiple mapping 
locations, and so on. Finally, SNVs with a low score were 
removed.
Candidate InDels were extracted from the CIGAR 
information in the BAM files. Next, the de Bruijn method 
was used to conduct the local de novo assemble based on the 
K-mers from the mapping reads (28). By comparison with 
the reference sequencing, InDels were predicted. InDels in 
the corresponding blood cell samples were removed. Finally, 
InDels in simple repeat regions of the human genome were 
checked again because of the possibility of more sequencing 
errors in these regions.
The method for detecting SNV/InDels in the ctDNA 
samples was the same as that for FFPE sequencing data, 
except for one additional step that was used to filter the raw 
mutant set. Twelve-bp paired reads were used as endogenic 
duplex consensus molecular barcodes and clustered (29). 
Those with identical barcodes and similar sequences (with 
consistency >80%) were considered duplication clusters of 
one template. The order of paired-end sequences was used 
to identify the sense and anti-sense strands of the template. 
Only the mutations with both sense and anti-sense strands 
were used for further analysis.
Somat i c  SNV and  InDel s  were  annota ted  by 
ANNOVAR, and only mutations that changed protein 
structure were retained for further analysis.
Figure S1 Clinical distribution of all SPNs. SPN, solitary pulmonary nodule; AAH, atypical adenomatous hyperplasia; AIS, adenocarcinoma 
in situ; MIA, minimally invasive adenocarcinoma; SCLC, small cell lung cancer.
Figure S2 Schedule of pulmonary nodules ultra-deep sequencing and mutation spectrum building. ctDNA, circulating tumour DNA.
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Figure S3 The mutational number comparison between stage I 
patients and stage II–III patients. 
Figure S4 The correlation between the number of ctDNA 
mutations and the size of SPN, which was measured by the 
maximum diameter of SPN. SPN, solitary pulmonary nodule; 
ctDNA, circulating tumour DNA.
Figure S5 The mutation overlap between the tissue DNA and 
the corresponding ctDNA sample. FFPE, formalin-fixed, paraffin 
embedded; ctDNA, circulating tumour DNA. 
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Table S1 Clinical information for the 38 sequencing samples analyzed in this st
Sample_ID Gender Age (year) Histology Primary site
Node size 
(maximum 
diameter) cm
Node size  
(D. max) cm
TNM Stage
CEA  
(ng/mL)
S32_N F 62 Benign Right sided 3.6 3.6×2.8×2.2 – – 1.24
S33_N F 53 Benign Right sided 1.2 1.2×1×1 – – 1.72
S34_N M 39 Benign Left sided 0.4 – – – 3.56
S35_N M 27 Benign Right sided 3 3×2.5×2 – – 1.07
S1_A F 55 Adenocarcinoma Right sided 2.5 2.5 T1bN2M0 IIIa 1.68
S2_A M 64 Adenocarcinoma Left sided 3.5 3.5×3×2.5 T1bN1M0 IIa 1.97
S3_A M 63 Adenocarcinoma Left sided 2 2 T1bN0M0 Ib 4.01
S4_A M 61 Adenocarcinoma Right sided 2.6 2.6×2×2 T1bN0M0 Ib 3.71
S5_A M 32 Adenocarcinoma Unknown 3.5 3.5 T1bN1M0 IIa 1.18
S6_A F 59 Adenocarcinoma Right sided 1.8 1.8×1.5×1.5 T1aN1M0 IIa 7.85
S7_A F 43 Adenocarcinoma Left sided 1.2 1.2×0.6 T1aN0M0 Ia 0.72
S8_A M 67 Adenocarcinoma Right sided 3.6 3.6×3 T2N1M0 IIa 1.8
S9_A F 47 Adenocarcinoma Right sided 2.5 2.5×2.5×2.2 T2N0M0 Ib 0.5
S10_A F 38 Adenocarcinoma Right sided 4 4×3.5×1.7 T2aNxMx 　 4.41
S11_A M 81 Adenocarcinoma Left sided 2 2×1.5 T1aN0M0 Ia 0.71
S29_O M 51 Other Right sided 2.3 2.3×1.3×0.7 T1bN2M0 IIIa 1.88
S12_A F 70 Adenocarcinoma Right sided 0.8 1.7×0.5 T1bN0M0 Ib 0.88
S13_A M 73 Adenocarcinoma Right sided 2 2×1.5 T2aN0M0 Ib 4.06
S14_A M 56 Adenocarcinoma Right sided 1.3 1.3×0.7×0.7 T1aN0M0 Ia 2.29
S15_A M 45 Adenocarcinoma Right sided 4 4×3×2.5 T2aN1M0a Iia 2.23
S16_A F 43 Adenocarcinoma Right sided 2 2×1×0.6 T1N0M0 Ia 18.15
S17_A M 50 Adenocarcinoma Left sided NA 2.7×2×1.5 T2aN0M0 Ib 1.44
S18_A F 60 Adenocarcinoma Right sided 1 1×1×1 T1aN0M0 Ia 0.55
S28_S M 69 Squamous cell carcinoma Left sided 3.5 3.5×3×3 T2aN0M0 Ib 2.2
S19_A M 52 Adenocarcinoma Right sided 3 3×2.7 T2aN2M0 IIIa 2.36
S20_A M 49 Adenocarcinoma Left sided 3 3×1.8 T1bN0M0 Ib 2.26
S30_O F 31 Other Right sided 1.3 1.3×1 T1aN0M0 Ia 0.55
S21_A F 60 Adenocarcinoma Left sided 1.3 1.3×0.5 T1aN0M0 Ia 1.41
S22_A M 70 Adenocarcinoma Right sided 2 2×1.8×1.5 T1aN0M0 Ia 1.63
S26_A M 59 AIS Left sided 0.8 0.8×0.5 T1aN0M0 Ia 2.15
S31_O M 72 Other Right sided 2 2×2×1.5 T1aN0M0 Ia 3.69
S27_A M 64 MIA Right sided 1 1×0.8 T1aN0M0 Ia 3.34
S23_A F 49 Adenocarcinoma Left sided 0.8 – T1aN0M0 Ia 1.36
S24_A M 66 Adenocarcinoma Right sided 1.8 1.8×1.7×1 T1aN0M0 Ia 1.93
S25_A M 68 Adenocarcinoma Left sided 3 3×2.5×2 T2aN3M0 IIIb 11.25
AIS, adenocarcinoma in situ; MIA, minimally invasive adenocarcinoma.
Table S3 Sequencing depth of each sample
Sample_ID
Depth
Normal Tissue ctDNA
S1_A 761 431 2,948
S10_A 702 636 1,479
S11_A 718 177 3,031
S12_A 765 386 5,643
S13_A 823 1,642 1,896
S14_A 1,428 402 5,889
S15_A 905 220 7,654
S16_A 1,370 275 7,484
S17_A 524 1,911 937
S18_A 801 833 4,454
S19_A 1,597 916 1,024
S2_A 728 197 2,596
S20_A 1,961 1,245 942
S21_A 1,922 601 1,856
S22_A 2,224 459 980
S23_A 1,362 362 805
S24_A 2,032 892 779
S25_A 1,952 818 1,424
S26_A 1,716 1,110 889
S27_A 1,820 1,072 892
S28_S 736 1,772 2,591
S29_O 911 542 3,035
S3_A 757 171 2,606
S30_O 1,803 513 704
S31_O 2,543 1,452 720
S32_N 672 1,089 3,732
S33_N 650 1,441 2,157
S34_N 1,829 1,113 1,593
S35_N 743 516 1,020
S4_A 659 465 3,559
S5_A 619 711 1,890
S6_A 845 268 1,894
S7_A 699 786 2,267
S8_A 660 520 2,275
S9_A 671 409 2,537
Table S2 All the gene list 
in the sequencing panel (27)
OR14C36
PARG
ERBB4
INSRR
DDR2
TMEM199
OR2T33
DSPP
KCNB2
ZNF479
ANAPC1
MB21D2
TSHZ3
MAP1B
THSD4
DNAH8
CNTN5
CDH10
KDR
EPB41L4A
TP53
OR4M2
SNAPC4
NTRK1
PTEN
OR51V1
ZFHX4
KRTAP4-8
NAV3
OR10Z1
PCDH11X
EPHA3
APC
SMAD4
STK11
ZNF804A
DDX11
FGFR4
OR2B11
DNMT3B
Table S2 (continued)
Table S2 (continued)
ZEB1
CDKN2A
NDUFS1
ADAM23
TBX6
XIRP2
FGFR1
MET
IL32
NTRK3
FAM135B
REG3A
KEAP1
PTPRD
RALGAPB
OR4C16
OR8H2
ATXN1
GAB1
JAK3
REG1B
LRRC56
FGFR2
DCAF4L2
KIAA2022
EPHA5
FGFR3
KIT
CROCC
CNTNAP3B
KRAS
CSNK2A1
INHBA
BRAF
FAM47A
AKT1
JAK2
NOTCH1
PRB2
PDGFRA
Table S2 (continued)
Table S2 (continued)
PBX2
WDR62
VAV3
CNTNAP2
CHEK2
KIAA0907
NUDT11
RYR2
LRRIQ3
OR4K2
FAM47C
KRTAP5-5
OR2M2
TNRC6A
VGLL3
OR2T34
RET
OR5D18
NF1
RB1
KLK1
FBN2
NRAS
OR4C15
LPA
MMP27
ATXN3
CTNNB1
GNA15
EGFR
ROS1
POTEC
MUC6
FBXW7
CDH12
OR5L2
NYAP2
CLIP1
KRTAP4-11
FOLH1
Table S2 (continued)
Table S2 (continued)
ZNF804B
PIK3CA
NOTCH2
OR2T2
ALK
AKAP6
NBPF10
NFE2L2
OR10G8
SH2D2A
MUC16
OR4N2
DHX9
ATM
PAPPA2
OR4N4
ERBB2
ZNF814
BEST3
ZNF598
Table S4 List of somatic SNV/InDels identified by FFPE samples sequencing data
Sample_ID Chr Start_POS End_POS Ref Mutational type Genotype Function Gene Transcript Exon Base mutation Protein mutation
S1_A chr7 55259438 55259439 T Snv T/G Missense EGFR NM_005228.3 EX21 c.[2497T>G];[=] p.[Leu833Val];[=]
S1_A chr7 55242468 55242484 TTAAGAGAAGCAACAT Del TTAAGAGAAGCAACAT/T Cds-indel EGFR NM_005228.3 EX19 c.[2240_2254delTAAGAGAAGCAACAT];[=] p.[Leu747_Ser752delinsSer];[=]
S1_A chr10 89717677 89717686 GAAGACAAG Del GAAGACAAG/G Frameshift PTEN NM_000314.4 EX7 c.[704_711delAAGACAAG];[=] p.[Glu235_Lys237delinsValfs*?];[=]
S2_A chr15 22368734 22368735 C Snv C/T Missense OR4M2 NM_001004719.2 EX1E c.160C>T p.H54Y | p.His54Tyr
S2_A chr15 22368880 22368881 C Snv C/A Missense OR4M2 NM_001004719.2 EX1E c.306C>A p.F102L | p.Phe102Leu
S2_A chr17 7577089 7577090 C Snv C/G Missense TP53 NM_000546.5 EX8 c.[848G>C];[=] p.[Arg283Pro];[=]
S3_A chr2 168105289 168105291 AG Del AG/A – XIRP2 NM_152381.5 intron g.[168105291delG];[=] .
S3_A chr7 88965976 88965977 C Snv C/A Missense ZNF804B NM_181646.2 EX4E c.3681C>A p.S1227R | p.Ser1227Arg
S3_A chr11 123901085 123901086 C Snv C/A Missense OR10G8 NM_001004464.1 – c.757C>A p.P253T | p.Pro253Thr
S3_A chr12 25398284 25398285 C Snv C/A Missense KRAS NM_004985.3 EX2 c.[34G>T];[=] p.[Gly12Cys];[=]
S3_A chr14 20296030 20296031 T Snv T/G Missense OR4N2 NM_001004723.1 – c.424T>G p.Y142D | p.Tyr142Asp
S3_A chr14 20296033 20296034 G Snv G/A Missense OR4N2 NM_001004723.1 – c.427G>A p.A143T | p.Ala143Thr
S3_A chr17 7578405 7578406 C Snv C/T Missense TP53 NM_000546.5 EX5 c.[524G>A];[=] p.[Arg175His];[=]
S3_A chr17 29559189 29559190 A Snv A/G Coding-synon NF1 NM_000267.3 EX25 c.[3297A>G];[=] p.[=];[=]
S3_A chr19 9073417 9073418 G Snv G/T Coding-synon MUC16 – – c.14028C>A .
S3_A chr19 58382263 58382264 T Snv T/C Utr-3 ZNF814 – – g.[58382264T>C];[=] .
S4_A chr1 156834221 156834222 T Ins T/TT Splice-5 NTRK1 NM_001007792.1 IVS3 c.[197+2_197+3insT];[=] .
S4_A chr1 162725076 162725077 C Snv C/T Coding-synon DDR2 NM_001014796.1 EX7 c.[549C>T];[=] p.[=];[=]
S4_A chr7 55242464 55242480 GGAATTAAGAGAAGCA Del GGAATTAAGAGAAGCA/G Cds-indel EGFR NM_005228.3 EX19 c.[2236_2250delGAATTAAGAGAAGCA];[=] p.[Glu746_Ala750delfs*?];[=]
S4_A chr17 7576853 7576855 TG Del TG/T Frameshift TP53 NM_000546.5 EX9 c.[991delC];[=] p.[Gln331Argfs*?];[=]
S4_A chr17 7579493 7579494 T Snv T/A Nonsense TP53 NM_000546.5 EX4 c.[193A>T];[=] p.[Arg65*];[=]
S4_A chr19 9060496 9060497 T Snv T/C Missense MUC16 – – c.26949A>G p.I8983M | p.Ile8983Met
S5_A chr15 88690675 88690676 G Snv G/A Intron NTRK3 NM_001007156.2 IVS5 c.[396-42C>T];[=] .
S6_A chr7 55259514 55259515 T Snv T/G Missense EGFR NM_005228.3 EX21 c.[2573T>G];[=] p.[Leu858Arg];[=]
S6_A chr15 88524578 88524582 TTTG Del TTTG/T Cds-indel NTRK3 NM_001007156.2 EX15 c.[1595_1597delCAA];[=] p.[Ser532_Asn533delinsTyr];[=]
S6_A chrX 91133541 91133542 T Snv T/A Missense PCDH11X – – c.2303T>A p.V768D | p.Val768Asp
S7_A chr7 55242477 55242478 G Snv G/C Missense EGFR NM_005228.3 EX19 c.[2248G>C];[=] p.[Ala750Pro];[=]
S7_A chr7 55242467 55242477 ATTAAGAGAA Del ATTAAGAGAA/A Cds-indel EGFR NM_005228.3 EX19 c.[2239_2247delTTAAGAGAA];[=] p.[Leu747_Glu749delfs*?];[=]
S8_A chr1 248616492 248616493 G Snv G/T – – – – g.[248616493G>T];[=] .
S8_A chr2 168103079 168103080 C Snv C/T – – – – g.[168103080C>T];[=] .
S8_A chr7 55249004 55249005 G Snv G/T Missense EGFR NM_005228.3 EX20 c.[2303G>T];[=] p.[Ser768Ile];[=]
S8_A chr7 55259514 55259515 T Snv T/G Missense EGFR NM_005228.3 EX21 c.[2573T>G];[=] p.[Leu858Arg];[=]
S8_A chr10 43610858 43610859 G Snv G/C Intron RET NM_020630.4 IVS11 c.[2136+675G>C];[=] .
S8_A chr15 88429074 88429076 CA Del CA/C Intron NTRK3 NM_001012338.2 IVS17 c.[2134-110delT];[=] .
S8_A chr17 7578190 7578191 A Ins A/ATA Frameshift TP53 NM_000546.5 EX6 c.[657_658insTA];[=] p.[Tyr220fs*?];[=]
S9_A chr7 55259514 55259515 T Snv T/G Missense EGFR NM_005228.3 EX21 c.[2573T>G];[=] p.[Leu858Arg];[=]
S9_A chr17 7578180 7578181 G Snv G/C Missense TP53 NM_000546.5 EX6 c.[668C>G];[=] p.[Pro223Arg];[=]
S9_A chr17 7579866 7579867 G Snv G/A Nonsense TP53 NM_000546.5 EX2 c.[46C>T];[=] p.[Gln16*];[=]
S9_A chrX 73960816 73960817 G Snv G/A Missense KIAA2022 – – c.[3575C>T];[=] p.[Ser1192Phe];[=]
S10_A chr7 55242469 55242470 T Snv T/C Missense EGFR NM_005228.3 EX19 c.[2240T>C];[=] p.[Leu747Ser];[=]
S10_A chr17 7577538 7577539 G Snv G/A Missense TP53 NM_000546.5 EX7 c.[742C>T];[=] p.[Arg248Trp];[=]
S11_A chr5 71495573 71495574 C Snv C/T Missense MAP1B – – c.[6392C>T];[=] p.[Pro2131Leu];[=]
S11_A chr8 139164634 139164635 C Snv C/T Missense FAM135B – – c.[2083G>A];[=] p.[Val695Ile];[=]
S11_A chr10 123256191 123256192 G Snv G/A Nonsense FGFR2 NM_000141.4 EX13 c.[1717C>T];[=] p.[Arg573*];[=]
S11_A chr7 55242463 55242479 AGGAATTAAGAGAAGC Del AGGAATTAAGAGAAGC/A Cds-indel EGFR NM_005228.3 EX19 c.[2235_2249delGGAATTAAGAGAAGC];[=] p.[Lys745_Ala750delinsLys];[=]
S29_O chr1 176564076 176564077 G Snv G/A Missense PAPPA2 NM_020318.2 EX3 c.[1337G>A];[=] p.[Ser446Asn];[=]
S29_O chr11 55595205 55595206 C Snv C/T Missense OR5L2 NM_001004739.1 EX1E c.[512C>T];[=] p.[Ser171Phe];[=]
S29_O chr13 48947637 48947638 A Snv A/G Intron RB1 NM_000321.2 IVS12 c.[1215+10A>G];[=] .
S12_A chr1 156843655 156843656 T Snv T/C Missense NTRK1 NM_001007792.1 EX9 c.[992T>C];[=] p.[Leu331Pro];[=]
S12_A chr1 248512497 248512498 A Snv A/G Missense OR14C36 NM_001001918.1 EX1E c.[422A>G];[=] p.[Gln141Arg];[=]
S12_A chr4 55139766 55139767 C Snv C/A Coding-synon PDGFRA NM_006206.4 EX10 c.[1428C>A];[=] p.[=];[=]
S12_A chr6 16328689 16328690 C Snv C/T Utr-5 ATXN1 NM_000332.3 EX8 c.[-149G>A];[=] .
S12_A chr7 55259514 55259515 T Snv T/G Missense EGFR NM_005228.3 EX21 c.[2573T>G];[=] p.[Leu858Arg];[=]
S12_A chr8 139207677 139207678 C Snv C/A Intron FAM135B NM_015912.3 IVS8 c.[824-128G>T];[=] .
S12_A chr15 88423539 88423540 G Snv G/A Coding-synon NTRK3 NM_001012338.2 EX19 c.[2295C>T];[=] p.[=];[=]
S12_A chr17 29575816 29575817 A Snv A/G Intron NF1 NM_000267.3 IVS29 c.[3975-185A>G];[=] .
S13_A chr1 74574911 74574912 A Snv A/G Intron LRRIQ3 NM_001105659.1 IVS5 c.[867+166T>C];[=] .
S13_A chr2 168100348 168100349 C Snv C/T Missense XIRP2 NM_001199144.1 EX7 c.[1781C>T];[=] p.[Pro594Leu];[=]
S13_A chr3 178951724 178951725 G Snv G/A Intron PIK3CA NM_006218.2 IVS20 c.[2937-157G>A];[=] .
S13_A chr4 55139556 55139557 C Snv C/T Intron PDGFRA NM_006206.4 IVS9 c.[1365-147C>T];[=] .
S13_A chr4 55976706 55976707 G Snv G/A Missense KDR NM_002253.2 EX9 c.[1118C>T];[=] p.[Ser373Phe];[=]
S13_A chr8 77618390 77618391 G Snv G/A Missense ZFHX4 NM_024721.4 EX2 c.[2068G>A];[=] p.[Glu690Lys];[=]
S13_A chr8 139164914 139164915 G Snv G/T Missense FAM135B NM_015912.3 EX13 c.[1803C>A];[=] p.[His601Gln];[=]
S13_A chr9 8341215 8341216 G Snv G/T Missense PTPRD NM_001040712.2 EX25 c.[3770C>A];[=] p.[Pro1257Gln];[=]
S13_A chr9 8486361 8486362 G Snv G/T Intron PTPRD NM_001040712.2 IVS11 c.[1814-1038C>A];[=] .
S13_A chr17 7577123 7577124 C Snv C/A Missense TP53 NM_000546.5 EX8 c.[814G>T];[=] p.[Val272Leu];[=]
S13_A chr17 29553464 29553465 G Snv G/A Missense NF1 NM_000267.3 EX18 c.[2014G>A];[=] p.[Gly672Arg];[=]
S13_A chr17 29592382 29592383 C Snv C/T Intron NF1 NM_000267.3 IVS35 c.[4772+26C>T];[=] .
S13_A chr19 1218272 1218273 C Snv C/T Intron STK11 NM_000455.4 IVS1 c.[291-143C>T];[=] .
S13_A chr19 31767735 31767736 G Snv G/T Missense TSHZ3 NM_020856.2 EX2E c.[2963C>A];[=] p.[Pro988His];[=]
S13_A chr19 31767736 31767737 G Snv G/T Missense TSHZ3 NM_020856.2 EX2E c.[2962C>A];[=] p.[Pro988Thr];[=]
S13_A chr19 31770028 31770029 C Snv C/T Missense TSHZ3 NM_020856.2 EX2E c.[670G>A];[=] p.[Asp224Asn];[=]
S13_A chr7 140453140 140453141 A Ins A/AACA Cds-indel BRAF NM_004333.4 EX15 c.[1793_1794insTGT];[=] p.[Ala598_Thr599insVal];[=]
S14_A chr7 55259514 55259515 T Snv T/G Missense EGFR NM_005228.3 EX21 c.[2573T>G];[=] p.[Leu858Arg];[=]
S14_A chr7 55260497 55260498 A Snv A/G Missense EGFR NM_005228.3 EX22 c.[2665A>G];[=] p.[Arg889Gly];[=]
S15_A chr6 117622322 117622323 G Snv G/A Intron ROS1 NM_002944.2 IVS41 c.[6570-23C>T];[=] .
S15_A chr7 140453135 140453136 A Snv A/T Missense BRAF NM_004333.4 EX15 c.[1799T>A];[=] p.[Val600Glu];[=]
S16_A chr17 7577533 7577534 C Snv C/A Missense TP53 NM_000546.5 EX7 c.[747G>T];[=] p.[Arg249Ser];[=]
S16_A chr7 55242463 55242479 AGGAATTAAGAGAAGC Del AGGAATTAAGAGAAGC/A Cds-indel EGFR NM_005228.3 EX19 c.[2235_2249delGGAATTAAGAGAAGC];[=] p.[Lys745_Ala750delinsLys];[=]
S17_A chr1 248511912 248511913 T Snv T/C – – – – g.[248511913T>C];[=] .
S17_A chr2 79313418 79313419 C Snv C/T Intron REG1B NM_006507.3 IVS4 c.[321+74G>A];[=] .
S17_A chr15 88726716 88726717 G Snv G/C Coding-synon NTRK3 NM_001007156.2 EX5 c.[327C>G];[=] p.[=];[=]
S17_A chr17 7579306 7579307 C Snv C/A Intron TP53 NM_000546.5 IVS4 c.[375+5G>T];[=] .
S17_A chr19 9060523 9060524 G Snv G/T Coding-synon MUC16 NM_024690.2 EX3 c.[26922C>A];[=] p.[=];[=]
S17_A chrX 34149098 34149099 C Snv C/A Missense FAM47A NM_203408.3 EX1E c.[1297G>T];[=] p.[Asp433Tyr];[=]
S18_A chr7 55259523 55259524 T Snv T/G Missense EGFR NM_005228.3 EX21 c.[2582T>G];[=] p.[Leu861Arg];[=]
S18_A chr17 7577558 7577559 G Snv G/A Missense TP53 NM_000546.5 EX7 c.[722C>T];[=] p.[Ser241Phe];[=]
S28_S chr4 55146560 55146561 G Snv G/A Missense PDGFRA NM_006206.4 EX16 c.[2235G>A];[=] p.[Met745Ile];[=]
S28_S chr7 41730105 41730106 G Snv G/C Coding-synon INHBA NM_002192.2 EX3E c.[423C>G];[=] p.[=];[=]
S28_S chr15 88524275 88524276 C Snv C/T Intron NTRK3 NM_001007156.2 IVS15 c.[1720+181G>A];[=] .
S28_S chr17 29576012 29576013 C Snv C/G Nonsense NF1 NM_000267.3 EX30 c.[3986C>G];[=] p.[Ser1329*];[=]
S19_A chr2 178098955 178098956 A Snv A/G Missense NFE2L2 NM_001145412.2 EX2 c.[41T>C];[=] p.[Leu14Pro];[=]
S19_A chr2 178098955 178098956 A Snv A/G Missense NFE2L2 NM_006164.4 EX2 c.[89T>C];[=] p.[Leu30Pro];[=]
S19_A chr7 55249028 55249029 G Snv G/A Missense EGFR NM_005228.3 EX20 c.[2327G>A];[=] p.[Arg776His];[=]
S19_A chr7 55259441 55259442 G Snv G/T Missense EGFR NM_005228.3 EX21 c.[2500G>T];[=] p.[Val834Leu];[=]
S19_A chr7 55259514 55259515 T Snv T/G Missense EGFR NM_005228.3 EX21 c.[2573T>G];[=] p.[Leu858Arg];[=]
S19_A chr10 31809949 31809950 G Snv G/A – – – – g.[31809950G>A];[=] .
S19_A chr18 48604672 48604673 T Snv T/C Missense SMAD4 NM_005359.5 EX12E c.[1495T>C];[=] p.[Cys499Arg];[=]
S19_A chr10 89720787 89720789 GG Del GG/G Frameshift PTEN NM_000314.4 EX8 c.[940delG];[=] p.[Glu314Lysfs*?];[=]
S19_A chr18 48584584 48584586 TT Del TT/T Frameshift SMAD4 NM_005359.5 EX6 c.[759delT];[=] p.[Phe253Leufs*?];[=]
S20_A chr2 212295788 212295789 G Snv G/A Missense ERBB4 NM_001042599.1 EX21 c.[2524C>T];[=] p.[Arg842Trp];[=]
S20_A chr15 22383188 22383189 G Snv G/A – – – – g.[22383189G>A];[=] .
S20_A chr19 1205807 1205808 C Snv C/T Utr-5 STK11 NM_000455.4 EX1 c.[-1105C>T];[=] .
S30_O chr14 20344974 20344975 G Snv G/A – – – – g.[20344975G>A];[=] .
S30_O chr15 22368861 22368862 G Snv G/A – – – – g.[22368862G>A];[=] .
S30_O chr15 22368904 22368905 G Snv G/A – – – – g.[22368905G>A];[=] .
S30_O chr15 22383188 22383189 G Snv G/A – – – – g.[22383189G>A];[=] .
S21_A chr3 41281604 41281605 T Ins T/TAATT – – – – g.[41281605_41281606insAATT];[=] .
S21_A chr7 55242467 55242480 ATTAAGAGAAGCA Del ATTAAGAGAAGCA/A Cds-indel EGFR NM_005228.3 EX19 c.[2239_2250delTTAAGAGAAGCA];[=] p.[Leu747_Ala750delfs*?];[=]
S34_N chr12 122812400 122812401 T Snv T/C – – – – g.[122812401T>C];[=] .
S22_A chr4 66217279 66217280 C Snv C/T Missense EPHA5 NM_004439.5 EX14 c.[2335G>A];[=] p.[Gly779Ser];[=]
S22_A chr7 55242493 55242494 C Snv C/G Missense EGFR NM_005228.3 EX19 c.[2264C>G];[=] p.[Ala755Gly];[=]
S22_A chr7 55242495 55242496 A Snv A/C Missense EGFR NM_005228.3 EX19 c.[2266A>C];[=] p.[Asn756His];[=]
S22_A chr7 57188855 57188856 G Snv G/A – – – – g.[57188856G>A];[=] .
S22_A chr9 8485833 8485834 G Snv G/A Missense PTPRD NM_002839.3 EX28 c.[2983C>T];[=] p.[Arg995Cys];[=]
S22_A chr17 39274363 39274364 T Snv T/G – – – – g.[39274364T>G];[=] .
S22_A chr7 55242468 55242487 TTAAGAGAAGCAACATCTC Del TTAAGAGAAGCAACATCTC/T Cds-indel EGFR NM_005228.3 EX19 c.[2240_2257delTAAGAGAAGCAACATCTC];[=] p.[Leu747_Pro753delinsSer];[=]
S26_A chr3 89448595 89448596 C Snv C/A Missense EPHA3 NM_005233.5 EX7 c.[1560C>A];[=] p.[Asn520Lys];[=]
S26_A chr7 140477829 140477845 TGAGGTGTAGGTGCTG Del TGAGGTGTAGGTGCTG/T Cds-indel BRAF NM_004333.4 EX12 c.[1463_1477delCAGCACCTACACCTC];[=] p.[Thr488_Gln493delinsLys];[=]
S26_A chr17 7579663 7579680 AGCCCTCCAGGTCCCCA Del A/A Intron TP53 NM_000546.5 IVS3 c.[96+20_96+35delTGGGGACCTGGAGGGC];[96+20_96+35delTGGGGACCTGGAGGGC] .
S31_O chr2 114357507 114357508 A Snv A/G – – – – g.[114357508A>G];[=] .
S31_O chr9 8504437 8504438 T Snv T/C Intron PTPRD NM_001040712.2 IVS10 c.[1669-33A>G];[=] .
S27_A chr17 39274156 39274157 G Snv G/A – – – – g.[39274157G>A];[=] .
S23_A chr6 117641473 117641474 G Snv G/A Intron ROS1 NM_002944.2 IVS35 c.[5778-281C>T];[=] .
S23_A chr19 9056988 9056989 C Snv C/G – – – – g.[9056989C>G];[=] .
S23_A chr19 9058623 9058624 G Snv G/A – – – – g.[9058624G>A];[=] .
S23_A chr19 10597049 10597050 G Snv G/A Utr-3 KEAP1 NM_012289.3 EX6E c.[*278C>T];[=] .
S23_A chr1 247615261 247615263 AA Del AA/A – – – – g.[247615263delA];[=] .
S23_A chr17 39253415 39253420 AGACA Del AGACA/A – – – – g.[39253417_39253420delGACA];[=] .
S24_A chr1 162724923 162724924 T Snv T/A Intron DDR2 NM_001014796.1 IVS6 c.[418-22T>A];[=] .
S24_A chr5 112174255 112174256 G Snv G/A Missense APC NM_000038.5 EX16E c.[2965G>A];[=] p.[Asp989Asn];[=]
S24_A chr7 55259514 55259515 T Snv T/G Missense EGFR NM_005228.3 EX21 c.[2573T>G];[=] p.[Leu858Arg];[=]
S24_A chr7 116412077 116412078 T Snv T/C Intron MET NM_000245.2 IVS14 c.[3028+35T>C];[=] .
S24_A chr7 116412077 116412078 T Snv T/C Intron MET NM_001127500.1 IVS14 c.[3082+35T>C];[=] .
S24_A chr9 8492980 8492981 T Snv T/C Splice-3 PTPRD NM_002839.3 IVS26 c.[2350-2A>G];[=] .
S25_A chr1 156844882 156844883 G Snv G/T Intron NTRK1 NM_001007792.1 IVS11 c.[1246+83G>T];[=] .
S25_A chr1 247615150 247615151 C Snv C/A – – – – g.[247615151C>A];[=] .
S25_A chr1 248616179 248616180 C Snv C/A – – – – g.[248616180C>A];[=] .
S25_A chr1 248737759 248737760 G Snv G/T – – – – g.[248737760G>T];[=] .
S25_A chr4 55960837 55960838 G Snv G/T Intron KDR NM_002253.2 IVS21 c.[2971+131C>A];[=] .
S25_A chr7 57187926 57187927 G Snv G/T – – – – g.[57187927G>T];[=] .
S25_A chr8 88886060 88886061 G Snv G/T – – – – g.[88886061G>T];[=] .
S25_A chr11 49168536 49168537 T Snv T/C – – – – g.[49168537T>C];[=] .
S25_A chr16 32890555 32890556 C Snv C/A – – – – g.[32890556C>A];[=] .
S25_A chr17 7578202 7578203 C Snv C/A Missense TP53 NM_000546.5 EX6 c.[646G>T];[=] p.[Val216Leu];[=]
S25_A chr17 7578202 7578203 C Snv C/A Missense TP53 NM_001276760.1 EX6 c.[529G>T];[=] p.[Val177Leu];[=]
S25_A chr17 7578204 7578205 C Snv C/A Missense TP53 NM_000546.5 EX6 c.[644G>T];[=] p.[Ser215Ile];[=]
S25_A chr19 1218413 1218414 A Snv A/G Splice-3 STK11 NM_000455.4 IVS1 c.[291-2A>G];[=] .
S25_A chr19 9060744 9060746 TT Del TT/T – – – – g.[9060746delT];[=] .
Table S6 List of somatic SNV/InDels identified in ctDNA samples
Sample_ID Chr Start_POS End_POS Ref Mutational type Genotype Function Gene Transcript Exon Base mutation Protein mutation
S4_A chr7 55266511 55266512 A Snv A/T Missense EGFR NM_005228.3 EX23 c.[2804A>T];[=] p.[Gln935Leu];[=]
S8_A chr7 55249004 55249005 G Snv G/T Missense EGFR NM_005228.3 EX20 c.[2303G>T];[=] p.[Ser768Ile];[=]
S8_A chr7 55259514 55259515 T Snv T/G Missense EGFR NM_005228.3 EX21 c.[2573T>G];[=] p.[Leu858Arg];[=]
S8_A chr10 43610858 43610859 G Snv G/C Intron RET NM_020630.4 IVS11 c.[2136+675G>C];[=] –
S14_A chr10 43610448 43610449 G Snv G/T Intron RET NM_020630.4 IVS11 c.[2136+265G>T];[=] –
S15_A chr7 55269080 55269081 G Snv G/T Intron EGFR NM_005228.3 IVS25 c.[3114+33G>T];[=] –
S15_A chr10 43610677 43610678 G Snv G/T Intron RET NM_020630.4 IVS11 c.[2136+494G>T];[=] –
S15_A chr10 43611827 43611828 T Snv T/A Intron RET NM_020630.4 IVS11 c.[2137-204T>A];[=] –
S27_A chr7 55219055 55219056 G Snv G/A Splice-5 EGFR NM_005228.3 IVS5 c.[628+1G>A];[=] –
S25_A chr6 117708978 117708979 A Snv A/C Missense ROS1 NM_002944.2 EX13 c.[1978T>G];[=] p.[Trp660Gly];[=]
Table S5 List of structure variation genes detected in FFPE samples
Sample_ID Gender Age Histology Gene1 Gene2 Cancer_SoftClip_Sup Normal_SoftClip_Sup All_freq (%) Validation by IHC
S5_A M 32 Adenocarcinoma ALK EML4 22 0 4.14 Yes
S27_A M 64 MIA KIF5B RET 46 0 5.79 Yes
S23_A F 49 Adenocarcinoma ALK EML4 29 0 4.65 Yes
S23_A F 49 Adenocarcinoma ERC1 ROS1 22 0 4.92 No
FFPE, formalin-fixed, paraffin embedded; MIA, minimally invasive adenocarcinoma.
SV calling
Chimeric read pairs were collected and clustered to detect 
structural variations (SVs). The clipped parts of the soft 
clipped reads were collected and mapped to the genome (30). 
Genome locations of clipped and remaining parts were 
clustered to determine the accurate break points of SVs.
ddPCR
Droplet digital PCR (ddPCR, QuantStudio 3D Digital 
PCR System, Life Technologies, Carlsbad, CA, USA) was 
performed in this study. According to the guidebooks, 
QuantStudio 3D Digital PCR Master Mix v2 and TaqMan 
Assay were thawed to room temperature and mixed 
approximately 10 times. The targeted DNA was diluted to 
200–2,000 copies/µL. The reaction mixture was prepared 
following the recommended protocol, and then the mixture 
was loaded into the QuantStudio 3D Digital PCR Chip as 
soon as possible.
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